DUSA Pharmaceuticals, Inc. (DUSA) is a vertically integrated dermatology company. The Company is developing and marketing Levulan photodynamic therapy (Levulan PDT). The Company�s marketed products include Levulan Kerastick 20% topical solution with PDT and the BLU-U brand light source. Levulan Kerastick and BLU-U are used for the treatment of non-hyperkeratotic actinic keratoses (AKs), of the face or scalp. During the year ended December 31, 2011, it initiated an exploratory DUSA-sponsored clinical trial designed to study the broad area application and/or short drug incubation (BASDI), method of using the Levulan Kerastick, which is being carried out at 10 clinical trial sites. DUSA manufactures its Levulan Kerastick in its Wilmington, Massachusetts facility. Its wholly owned subsidiaries include DUSA Pharmaceuticals New York, Inc. and Sirius Laboratories, Inc. As of December 31, 2011, DUSA ceased marketing and selling its remaining Non-PDT products, which were ClindaReach and Meted.